by The Italy peptide receptor radionuclide therapy market offers targeted treatment through radiolabeled receptor-binding peptides used for imaging and therapy of cancer. Peptide receptor radionuclide therapy helps in diagnosing and treating certain types of cancer with the use of radioactive substances coupled to peptides that bind to receptors on cancer cell surfaces.
The global Italy Peptide Receptor Radionuclide Therapy Market is estimated to be valued at US$ 681.79 Mn in 2024 and is expected to exhibit a CAGR of 7.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing demand for targeted radiotherapy: Targeted radiotherapy uses radioactive materials linked to molecules such as monoclonal antibodies, peptides or small molecules that bind to receptors on tumor cells. This helps deliver higher doses of radiation directly to the tumor while limiting radiation exposure to normal tissues. Peptide receptor radionuclide therapy is gaining popularity in Italy due to its potential to deliver high doses of radiation directly to cancer cells with minimal side effects. The rising demand for targeted and personalized treatment approaches is expected to drive the Italy peptide receptor radionuclide therapy market growth over the forecast period.
SWOT Analysis
Strength: Italy peptide receptor radionuclide therapy market has strong presence of key players who continuously invest in R&D. Growing cancer prevalence in Italy also drives the market growth.
Weakness: High costs associated with peptide receptor radionuclide therapy drugs restrict wider adoption. Strict regulationsrelated toapproval of new drugs also impacts the market introduction of novel therapies.
Opportunity: Increasing healthcare expenditure in Italy creates opportunities for market players. Rising elderly population who are at high risk of cancer also presents lucrative opportunities.
Threats: Preference for alternative non-drug treatment procedures threatens peptide receptor radionuclide therapy adoption. Adverse effects related to drugs also poses challenges.
Key Takeaways
The global Italy peptide receptor radionuclide therapy market is expected to witness high growth over the forecast period of 2024 to 2031. Italy Peptide Receptor Radionuclide Therapy Market Size is estimated to be valued at US$ 681.79 Mn in 2024 and is expected to exhibit a CAGR of 7.8% over the forecast period 2024 to 2031.
The Italy market dominates the European region and is projected to grow at a CAGR of 7% during the forecast period. This is majorly attributed to presence of advanced healthcare infrastructure and increasing government initiatives to raise cancer awareness.
Key players
Key players operating in the Italy peptide receptor radionuclide therapy market are Novartis AG, Australian Radionuclides, IPTN, BAE, ANSTO and Best Theratronics. Novartis AG dominates the market with wide product portfolio offering peptide receptor radionuclide therapies for treating various cancers including neuroendocrine tumors.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
